Home


Login | Forgot password?
June 20, 2013
A new path to hope

Brainsgate is a medical device company committed to developing a novel treatment modality, electrical SPG stimulation. This platform technology has been shown to increase blood flow to the brain and as a result has broad potential for treating central nervous system disorders. BrainsGate is currently focusing on:

1. Improve the outcome of patients suffering from ischemic stroke, in a 24 hour window after onset of symptoms.

2. Long-term SPG stimulation for the treatment of vascular dementia patients.


Focus: ISS
BrainsGate's product for the treatment of ischemic stroke and vascular dementia read more
Focus: Stroke
The leading cause of adult long-term disability and the third leading cause of death read more
March 29, 2012
Best Practices Symposium
Gearing up towards the ImpACT-24B Best Practices Symposium in Italy, March 2012... > full story
May 26, 2011
ImpACT-24b Trial Launch
BrainsGate launches the ImpACT-24b at the European Stroke Conference 2011 in Hamburg > full story